Harbin Medisan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
October 26, 2021 at 09:15 am
Share
Harbin Medisan Pharmaceutical Co., Ltd. reported earnings results for the nine months ended September 30, 2021. For the nine months, the company reported sales was CNY 707.66 million compared to CNY 966.46 million a year ago. Revenue was CNY 707.66 million compared to CNY 966.46 million a year ago. Net income was CNY 539.75 million compared to CNY 22.16 million a year ago. Basic earnings per share from continuing operations was CNY 1.74 compared to CNY 0.07 a year ago. Diluted earnings per share from continuing operations was CNY 1.74 compared to CNY 0.07 a year ago.
HARBIN MEDISAN PHARMACEUTICAL CO LTD is a China-based company principally engaged in the research and development, production and sales of chemical preparations, active pharmaceutical ingredients (APIs), medical devices and cosmetics. Its medicines cover the nervous system, cardio-cerebrovascular, systemic anti-infection, musculoskeletal, nutritional infusion, and body fluid balance infusion therapeutic fields. The Company's products include freeze-dried powder injections, small volume injections, large infusion products, solid preparations, medical devices and cosmetics. The Company mainly distributes its products within domestic market.